Weidong Han (Wenbin Qian)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Natural Killer Cells

Mesenchymal Stem Cells

Helicobacter Pylori

Top Venues

Experimental hematology & oncology

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Wen Lei, Ai Zhao, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Guifang Ouyang, Ming Liu, Jinyi Zhang, Jimin Gao, Weidong Han
Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell discovery 10 (1) (2024)
Shanshan Guo, Wen Lei, Xueli Jin, Hui Liu, James Q Wang, Wenhai Deng, Weidong Han
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood advances 8 (11) (2024)
Wen Lei, Ai Zhao, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Guifang Ouyang, Ming Liu, Jinyi Zhang, Jimin Gao, Weidong Han
Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell discovery 10 (1) (2024)
Shanshan Guo, Wen Lei, Xueli Jin, Hui Liu, James Q Wang, Wenhai Deng, Weidong Han
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood advances 8 (11) (2024)
Wen Lei, Ai Zhao, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Guifang Ouyang, Ming Liu, Jinyi Zhang, Jimin Gao, Weidong Han
Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell discovery 10 (1) (2024)
Lina Zhou, Shuai Wang, Wei Hu, Xiaoqian Liu, Lingdong Xu, Bolu Tong, Tongtong Zhang, Zhonghui Xue, Yixin Guo, Jing Zhao, Linrong Lu, Heng-Yu Fan, Weidong Han, Jian Chen, Wei J Chen, Lie Wang
T cell proliferation requires ribosomal maturation in nucleolar condensates dependent on DCAF13. The Journal of cell biology 222 (10) (2023)
Zijun Y Xu-Monette, Yong Li, Thomas Snyder, Tiantian Yu, Tingxun Lu, Alexandar Tzankov, Chiara Rusconi, Govind Bhagat, Weidong Han, Karen Dybkær, April Chiu, Wayne Tam, Youli Zu, Eric D Hsi, Fredrick B Hagemeister, Yingjun Wang, Heounjeong Go, Maurilio Ponzoni, Andrés José Maria Ferreri, Michael Boe Møller, Benjamin M Parsons, Xiangshan Fan, J Henricus van Krieken, Miguel Angel Piris, Jane N Winter, Qingyan Au, Ilan R Kirsch, Ming-Zhi Zhang, John Shaughnessy, Bing Xu, Ken H H Young
Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Mengyuan Li, Minghuan Zhang, Qian Ye, Yun-Hua Liu, Weidong Han
Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review. Cancer biology & medicine (2023)
Wen Lei, Qian Ye, Yuanyuan Hao, Jie Chen, Yu Huang, Liu Yang, Shibing Wang, Weidong Han
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma. Blood cancer journal 12 (2) (2022)
Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian
Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials. Cancer communications (London, England) 42 (6) (2022)
Wenhai Deng, Panpan Chen, Wen Lei, Yang Xu, Nengwen Xu, Jeffrey J Pu, Aibin Liang, Weidong Han
CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. Cancer communications (London, England) 41 (9) (2021)
Xiaolei Li, Hanren Dai, Xian Li, Ping Li, Weidong Han, Aibin Liang, Weidong Han
Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done? Cellular & molecular immunology (2021)
Wen Lei, Mixue Xie, Qi Jiang, Nengwen Xu, Ping Li, Aibin Liang, Ken H Young, Weidong Han
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers 13 (15) (2021)
Nengwen Xu, Linjie Li, Wen Lei, Weidong Han
Nocardia farcinica Brain Abscess in a Multiple Myeloma Patient Treated with Proteasome Inhibitor: A Case Report and Review of the Literature. Brain sciences 11 (9) (2021)
Changqian Bao, Xiandong Tao, Wei Cui, Yuanyuan Hao, Shuaike Zheng, Bin Yi, Tiewen Pan, Ken H Young, Weidong Han
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients. Experimental hematology & oncology 10 (1) (2021)
Caiqin Xie, Xian Li, Hui Zeng, Weidong Han
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. Experimental hematology & oncology 9 (1) (2020)
Changqian Bao, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H Young, Weidong Han
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Experimental hematology & oncology 9 (2020)
Chunmei Yang, Mixue Xie, Kaifeng Zhang, Hui Liu, Ai-Bin Liang, Ken H H Young, Weidong Han
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia 34 (11) (2020)
Jianshu Wei, Yang Liu, Chunmeng Wang, Yajing Zhang, Chuan Tong, Guanghai Dai, Wei Wang, John E J Rasko, J Joseph Melenhorst, Weidong Han, Aibin Liang, Weidong Han
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal transduction and targeted therapy 5 (1) (2020)